Macquarie Group Ltd. reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 13.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 4,600 shares of the medical equipment provider’s stock after selling 700 shares during the quarter. Macquarie Group Ltd.’s holdings in Hologic were worth $189,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors also recently bought and sold shares of the company. Lindbrook Capital LLC acquired a new stake in shares of Hologic during the fourth quarter worth $36,000. Essex Savings Bank acquired a new position in Hologic during the fourth quarter valued at $37,000. Cerebellum GP LLC acquired a new position in Hologic during the fourth quarter valued at $43,000. Clean Yield Group acquired a new position in Hologic during the fourth quarter valued at $47,000. Finally, Bronfman E.L. Rothschild L.P. lifted its position in Hologic by 90.1% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,194 shares of the medical equipment provider’s stock valued at $49,000 after purchasing an additional 566 shares during the period. Institutional investors and hedge funds own 89.91% of the company’s stock.
HOLX has been the subject of a number of research reports. TheStreet upgraded shares of Hologic from a “c” rating to a “b” rating in a research report on Monday, March 4th. BTIG Research restated a “buy” rating and set a $50.00 target price on shares of Hologic in a research report on Thursday, January 31st. Needham & Company LLC restated a “buy” rating and set a $50.00 target price (up from $48.00) on shares of Hologic in a research report on Thursday, January 31st. ValuEngine upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research report on Friday, February 15th. Finally, BidaskClub downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 4th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and five have assigned a buy rating to the company. Hologic has an average rating of “Hold” and an average price target of $44.52.
Shares of Hologic stock opened at $45.79 on Wednesday. The stock has a market capitalization of $13.70 billion, a price-to-earnings ratio of 20.72, a PEG ratio of 2.21 and a beta of 0.75. Hologic, Inc. has a fifty-two week low of $35.10 and a fifty-two week high of $48.82. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.30 and a quick ratio of 0.91.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, January 30th. The medical equipment provider reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.01. The business had revenue of $830.70 million during the quarter, compared to the consensus estimate of $823.22 million. Hologic had a negative net margin of 12.88% and a positive return on equity of 25.59%. The company’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.55 earnings per share. On average, sell-side analysts predict that Hologic, Inc. will post 2.41 earnings per share for the current year.
Hologic Company Profile
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: How does inflation affect different investments?
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.